REGENERATIVE MEDICINE – Page 40 – REGENHEALTHSOLUTIONS (RHS)

PIER MARIA FORNASARI
2019-09-20

AveXis presents new data at EPNS continuing to show significant therapeutic benefit of Zolgensma® in prolonging event-free survival now up to 5 years of age in patients with spinal muscular atrophy (SMA) Type 1

New interim data from SPR1NT study supports critical importance of early intervention in pre-symptomatic SMA patients, leading to age‑appropriate major milestone gain Updated results from global STR1VE study demonstrate that Zolgensma® (onasemnogene abeparvovec-xioi) has significant therapeutic benefit in prolonging event-free survival in SMA Type 1 patients versus natural history Patients in START long-term follow-up study (cohort 2), who

No Comments InGENE THERAPY RARE DISEASES

PIER MARIA FORNASARI
2019-09-19

Boston University researchers create new protocol to improve gene therapy tool production

Method is more efficient and economical compared with other procedures A method to create a faster and lower cost alternative for a gene therapy tool has been developed by Boston University School of Medicine (BUSM) researchers. Gene therapy is a clinical technique that introduce genes to treat disease. One approach is to use adeno-associated virus

No Comments InGENE THERAPY RARE DISEASES

PIER MARIA FORNASARI
2019-09-19

Success of nearly half of European cancer drug trials ‘exaggerated’ due to bias: report

In new research looking at pivotal trials for new cancer drugs approved by the European Medicines Agency between 2014 and 2016, researchers found only a quarter of trials use overall survival as a primary endpoint. Trials for cancer drugs undertaken in Europe in the mid-2010s were flawed to such a degree as to “raise questions”

No Comments InEMA

PIER MARIA FORNASARI
2019-09-19

Senescent Cell Burden Is Reduced in Humans by Senolytic Drugs following Mayo Clinic research

In a small safety and feasibility clinical trial, Mayo Clinic researchers have demonstrated for the first time that senescent cells can be removed from the body using drugs termed “senolytics”. The result was verified not only in analysis of blood but also in changes in skin and fat tissue senescent cell abundance. This trial —

No Comments InAGEING

PIER MARIA FORNASARI
2019-09-19

FDA Grants Breakthrough Therapy Designation for Genentech’s Gazyva (Obinutuzumab) in Lupus Nephritis

The designation is based on the results of the Phase II NOBILITY study that showed Gazyva, in combination with standard of care, helped more people achieve a complete renal response than standard of care alone Genentech today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to Gazyva® (obinutuzumab) for

No Comments InAUTOIMMUNE DISEASES

PIER MARIA FORNASARI
2019-09-19

SanBio Granted Regenerative Medicine Advanced Therapy Designation from the U.S. FDA for SB623 for the Treatment of Chronic Neurological Motor Deficits Secondary to Traumatic Brain Injury

The SanBio Group, a scientific leader in regenerative medicine for neurological disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) Designation for SB623 cell therapy for the treatment of chronic neurological motor deficits secondary to traumatic brain injury (TBI). The designation is based on clinical results

No Comments InBRAIN

PIER MARIA FORNASARI
2019-09-19

Brain implant restores visual perception to the blind

With wireless device, people without sight can detect motion, distinguish light and dark Source UCLA Health Seven years ago, Jason Esterhuizen was in a horrific car crash that destroyed his eyes, plunging him into total darkness. Today, he’s regained visual perception and more independence, thanks to an experimental device implanted in his brain by researchers

No Comments InBRAIN

PIER MARIA FORNASARI
2019-09-19

New cells identified that repair tissue

Researchers at Oxford University have discovered that a newly discovered group of cells can help repair tissues in the body. The researchers, who are supported by the NIHR Oxford Biomedical Research Centre, say these cells, which are abundant in our bodies, could be harnessed to help heal tissues and treat diseases such as infections of

No Comments InREGENERATIVE MEDICINE

PIER MARIA FORNASARI
2019-09-18

Zylka Lab awarded $6.1 million from NIH to develop CRISPR/Cas9 gene therapy for Angelman syndrome, study UBE3A autism gene with Philpot Lab

Mark Zylka, PhD, in The UNC Neuroscience Center was awarded NIH funding for two 5-year projects, one jointly with Ben Philpot, PhD, to develop new knowledge with the potential to advance treatments for neurodevelopmental disorders. The National Institutes of Health have awarded two separate grants totaling $6.1 million to Mark Zylka, PhD, director of the

No Comments InGENE THERAPY RARE DISEASES

PIER MARIA FORNASARI
2019-09-18

AAV9 Edits Muscle Stem Cells in Normal and Dystrophic Adult Mice

CRISPR Research Might Lead to Cure for Duchenne Muscular Dystrophy At this time, there is no cure for Duchenne muscular dystrophy (DMD), although there is one treatment for a subgroup of the disease. That is Sarepta Therapeutics’ Exondys 51 for DMD patients with a confirmed mutation amenable to exon 51 skipping. Recently the U.S. Food and

No Comments InGENE THERAPY RARE DISEASES

REGENERATIVE AND PERSONALISED MEDICINE

DIGITAL HEALTHCARE

Category REGENERATIVE MEDICINE

AveXis presents new data at EPNS continuing to show significant therapeutic benefit of Zolgensma® in prolonging event-free survival now up to 5 years of age in patients with spinal muscular atrophy (SMA) Type 1

Boston University researchers create new protocol to improve gene therapy tool production

Success of nearly half of European cancer drug trials ‘exaggerated’ due to bias: report

Senescent Cell Burden Is Reduced in Humans by Senolytic Drugs following Mayo Clinic research

FDA Grants Breakthrough Therapy Designation for Genentech’s Gazyva (Obinutuzumab) in Lupus Nephritis

SanBio Granted Regenerative Medicine Advanced Therapy Designation from the U.S. FDA for SB623 for the Treatment of Chronic Neurological Motor Deficits Secondary to Traumatic Brain Injury

Brain implant restores visual perception to the blind

New cells identified that repair tissue

Zylka Lab awarded $6.1 million from NIH to develop CRISPR/Cas9 gene therapy for Angelman syndrome, study UBE3A autism gene with Philpot Lab

AAV9 Edits Muscle Stem Cells in Normal and Dystrophic Adult Mice